Related Experiment Videos
High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis
Bu-Chun Zhang1, Wei-Ming Li, Ya-Wei Xu
1Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Insights
Short-term high-dose statin pretreatment effectively reduces contrast-induced nephropathy (CIN) and serum creatinine levels in patients undergoing contrast procedures. However, it does not benefit those with pre-existing renal impairment.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Contrast-induced nephropathy (CIN) is a significant complication of contrast-based medical procedures.
- Statins are investigated for CIN prevention, but clinical outcomes have been inconsistent.
- Understanding optimal statin use for CIN prevention is crucial for patient care.
Purpose of the Study:
- To evaluate the efficacy of short-term, high-dose statin administration versus conventional doses or placebo in preventing CIN.
- To assess the impact of statin pretreatment on serum creatinine levels post-procedure.
- To determine if statin effectiveness varies in patients with pre-existing renal impairment.
Main Methods:
- A meta-analysis of 8 randomized clinical trials involving 1423 patients.
- Pooled analysis of data to compare short-term high-dose statin therapy with control groups.
- Subgroup analysis to assess outcomes in patients with pre-existing renal impairment.
Main Results:
- Short-term high-dose statin treatment significantly decreased CIN occurrence (RR 0.51, P=0.001).
- High-dose statins also reduced 48-hour serum creatinine levels (SMD -0.07 mg/dL, P<0.00001).
- No significant reduction in CIN was observed in patients with pre-existing renal impairment (RR 0.90, P=0.73).
Conclusions:
- Short-term high-dose statin pretreatment is effective in reducing CIN and serum creatinine levels in patients undergoing contrast procedures.
- Statin pretreatment did not show benefit for CIN prevention in patients with pre-existing renal impairment.
- Further prospective trials are recommended to confirm these findings and establish definitive conclusions.
Background:
Contrast-induced nephropathy (CIN) is a rare but serious complication following contrast-based procedures. Statins have been postulated to prevent CIN via various mechanisms. However, the outcomes following statin administration to prevent CIN have been inconsistent.
Methods:
A meta-analysis of published randomized clinical trials was performed to determine if short-term administration of high-dose statin is superior to conventional-dose statin or placebo among patients undergoing catheterization and interventional procedures in preventing CIN.
Results:
Data were combined across 8 published clinical trials in which 1423 patients were identified. Pooled analyses showed that short-term high-dose statin treatment can decrease the occurrence of CIN (risk ratio 0.51, 95% confidence interval [CI], 0.34-0.77; P=0.001) and 48-hour serum creatinine level (standardized mean difference [SMD] -0.07 mg/dL; 95% CI, -0.11 to -0.04 mg/dL; P<0.00001). However, subgroup analysis showed that statin pretreatment cannot decrease the occurrence of CIN in patients with preexisting renal impairment (RR 0.90; 95% CI, 0.49-1.65; P=0.73). No evidence of publication bias was detected.
Conclusions:
This meta-analysis supports the effectiveness of short-term high-dose statin pretreatment for both decreasing the level of serum creatinine and reducing the rate of CIN in patients undergoing diagnostic and interventional procedures requiring contrast media. However, prospective clinical trials will be needed to draw a definitive conclusion in this area.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance
Imaging Studies for Cardiovascular System V: CT
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions